NeuBase Therapeutics Received A Notice On April 4, 2024 From The Listing Qualifications Department Of The Nasdaq Stock Market Notifying The Company That It Was Not In Compliance With Nasdaq's Continued Listing Requirements Under Nasdaq Listing Rule 5250(c)(1)